Golestan University of Medical Sciences Repository

Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy

Nezami, N. and Safa, J. and Salari, B. and Ghorashi, S. and Khosraviani, K. and Davari-Farid, S. and Hashemi-Aghdam, Y. and Nargabad, O.N. and Tabrizi, J.S. (2012) Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy. Nucleosides, Nucleotides and Nucleic Acids, 31 (4). pp. 353-363. ISSN 15257770 (ISSN)

Full text not available from this repository.


Background/aim: A high uric acid (UA) level is demonstrated as a major risk factor of nephropathy and cardiovascular events in people with type 2 diabetes (T2D). This study aimed to evaluate the lovastatin effect on serum UA levels in people with type 2 diabetic nephropathy (T2DN). Methods: Thirty patients completed the study course, out of 38 adult male patients with T2DN who were initially enrolled. Lovastatin, 20 mg/d, was administered for 90 days. Afterwards, lovastatin was withdrawn for the next 30 days. Blood samples were obtained at baseline, after 45 and 90 days of intervention, and 30 days after the withdrawal of lovastatin. The serum level of UA was assessed by the uricase/PAP method. The lipid profile and high-sensitivity C-reactive protein (hs-CRP) were determined using commercial reagents and the ELISA method. Results: After 90 days of lovastatin intervention, cholesterol (Chol) and low-density lipoprotein cholesterol (LDL-C) levels significantly decreased and the high-density lipoprotein cholesterol (HDL-C) level increased significantly, despite the unchanged level of triglyceride (TG). After withdrawal, Chol, TG, and LDL-C levels were significantly increased, without any change in the HDL-C level. The baseline serum UA level was 5.9±4 2.02 mg/dL and not changed after the intervention (5.95±2.21 mg/dL; p = 0.969) and withdrawal period (5.80±1.51 mg/dL; p = 0.647). The changes of serum UA levels were not correlated with the changes of serum hs-CRP levels, both after intervention and withdrawal (p = 0.963 & p = 0.835). Conclusions: Lovastatin does not have any effect on the serum UA level in people with T2DN. There is no correlation between the anti-lipidemic and anti-inflammatory effects of lovastatin and its effect on serum UA. Copyright © Cejera, LLC.

Item Type: Article
Additional Information: Unmapped bibliographic data: LA - English [Field not mapped to EPrints] J2 - Nucleosides Nucleotides Nucleic Acids [Field not mapped to EPrints] C2 - 22444196 [Field not mapped to EPrints] AD - Clinical Pharmacy Laboratory, Drug Applied Research Center, Tabriz University of Medical Sciences, Pashmineh, Daneshgah Street, Tabriz, Eastern Azerbaijan, Iran [Field not mapped to EPrints] AD - Department of Nephrology, Tabriz University of Medical Sciences, Tabriz, Iran [Field not mapped to EPrints] AD - Young Researchers Club, Tabriz Branch, Islamic Azad University, Tabriz, Iran [Field not mapped to EPrints] AD - Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY, United States [Field not mapped to EPrints] AD - Bagiyatollah Azam Hospital, Golestan University of Medical Sciences, Aliabad Katool, Golestan, Iran [Field not mapped to EPrints] AD - Health Services Management Research Center (NPMC), Faculty of Health and Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran [Field not mapped to EPrints] DB - Scopus [Field not mapped to EPrints]
Uncontrolled Keywords: diabetes, HMG-CoA reductase inhibitor, lovastatin, nephropathy, statin, Uric acid, C reactive protein, cholesterol, hemoglobin A1c, high density lipoprotein cholesterol, low density lipoprotein cholesterol, mevinolin, triacylglycerol, adult, aged, article, blood sampling, cholesterol blood level, clinical article, diabetic nephropathy, diabetic patient, drug efficacy, drug withdrawal, enzyme linked immunosorbent assay, human, human tissue, lipid analysis, male, non insulin dependent diabetes mellitus, treatment duration, treatment response, triacylglycerol blood level, uric acid blood level, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Fasting, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipids, Lovastatin, Male, Middle Aged, Time Factors, Uric Acid, Withholding Treatment
Subjects: مقالات نمایه شده محققین دانشگاه در سایت ,Web of Science ,Scopus
Divisions: معاونت تحقیقات و فناوری
Depositing User: GOUMS
Date Deposited: 19 Apr 2015 07:00
Last Modified: 15 Jun 2015 06:43
URI: http://eprints.goums.ac.ir/id/eprint/2026

Actions (login required)

View Item View Item